Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Astepro vs Astelin in chronic allergic or nonallergic rhinitis
NCT00783432Phase 3Completed
- Sponsor
- Meda
- Start
- Jul 2006
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of azelastine in allergic rhinitis (AR) and non-allergic rhinitis (NAR) (2 arms), sponsored by Meda. Primary endpoints: Number of Participants Reporting Adverse Events at 12 months and Focused Examination of the Head and Neck at 12 months. Started Jul 2006; status: completed.
02
Drugs
azelastine
03
Conditions
allergic rhinitis (AR)non-allergic rhinitis (NAR)
Beyond the preview
Go deeper on NCT00783432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00783432.